论文部分内容阅读
The clinical features of necrobiotic xanthogranuloma (NX)have been presented in a series of case reports, but there are hardly any reports on the clinical long- term course of this rare and usually chronic entity. Therapeutic recommendations are mostly based on individual observations, lacking general therapeutic guidelines. To illustrate a typical chronic and progressive course of NX, we report the case of a 64- year- old woman with periorbital NX, ocular involvement and IgG paraproteinemia. Diagnosed with NX for the first time in 1993, the patient was already presented in this journal in 1995. Since then a series of therapeutic options including medication with dapsone, chlorambucil, interferon- alpha, clofazimine, melphalan, fumaric acid esters, surgical treatment and other physical therapies such as radiation, plasmapheresis, and photodynamic therapy have been applied. None of these therapeutic approaches, however, showed a satisfying long- term effect. At present the patient is undergoing cyclophosphamide- dexamethasone pulse therapy.
The clinical features of necrobiotic xanthogranuloma (NX) have been presented in a series of case reports, but there are hardly any reports on the clinical long- term course of this rare and usually chronic entity. Therapeutic recommendations are mostly based on individual observations, lacking general instruction guidelines. To illustrate a typical chronic and progressive course of NX, we report the case of a 64- year-old woman with periorbital NX, ocular involvement and IgG paraproteinemia. Diagnosed with NX for the first time in 1993, the patient was already presented in this journal in 1995. Since then a series of therapeutic options including medication with dapsone, chlorambucil, interferon-alpha, clofazimine, melphalan, fumaric acid esters, surgical treatment and other physical therapies such as radiation, plasmapheresis, and photodynamic therapy have None applied these, however, showed a satisfying long-term effect. At present the patient is un dergoing cyclophosphamide-dexamethasone pulse therapy.